

ASX ANNOUNCEMENT

Capital Raising to raise up to \$1.593 million

18 September 2017: Analytica Limited (ASX:ALT) (**Company**) is pleased to announce that it is proposing to undertake an equity capital raising to raise up to approximately \$1.593 million (before offer costs) by way of a renounceable pro-rata entitlement offer to eligible shareholders (**Entitlement Offer**).

Terms of the Entitlement Offer

The Entitlement Offer will offer one new share for every eight shares held at the record date at an issue price of 0.5¢ per new share

For every share subscribed for the Company will issue:

- 1 option exercisable at 0.5¢ on or before 31 January 2018; and
- 1 option exercisable at 0.5¢ on or before 31 May 2018.

The options will not be quoted.

The Entitlement Offer is not underwritten, but shareholders who have fully subscribed for their Entitlement Offer entitlement may subscribe for additional shares and attaching options in excess of their entitlement under any shortfall. The Company reserves the right to allot and issue any shortfall shares at its discretion.

Shareholders on the register at 7pm (AEDST) on 21 September 2017 will be entitled to participate in the Entitlement Offer. More information regarding the Entitlement Offer will be set out in the prospectus, to be mailed to eligible shareholders in accordance with the timetable below.

The shares issued under the Entitlement Offer will rank equally in all respects with the Company's existing fully paid ordinary shares.

Existing option holders should note that in order to be able to participate in the Entitlement Offer they will need to exercise their options. Further details will be provided to option holders separately.

Use of Funds:

Net proceeds from the Entitlement Offer will be used by the Company to fund the development of the PeriCoach System and for general working capital.

Indicative Timetable

The indicative timetable for the Entitlement Offer is set out below. Please note that this timetable is indicative only. The Company reserves the right to amend this indicative timetable at any time, subject to the *Corporations Act 2001 (Cth)* and the ASX Listing Rules.

Event	Date
Prospectus Lodged	Monday, 18 September 2017
Existing shares quoted on an 'ex-rights' basis, Rights Trading commences	Wednesday, 20 September 2017
Record Date	Thursday, 21 September 2017



Event	Date
Entitlement Offer opens Prospectus dispatched	Tuesday, 26 September 2017
Rights trading ends	Thursday, 5 October 2017
Entitlement Offer closes	5pm Sydney Time, Thursday, 12 October 2017
Announcement of shortfall (if any) under the Entitlement Offer	Tuesday, 17 October 2017
Allotment date of new shares and options issued under the Entitlement Offer	Thursday, 19 October 2017
Dispatch of holding statements for New Shares issued under the Entitlement Offer. Normal trading of New Shares issued under the Entitlement Offer	Friday, 20 October 2017

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland, and in the USA.

